| scholarly article | Q13442814 |
| P50 | author | Ryosuke Okamura | Q56452025 |
| Razelle Kurzrock | Q56614941 | ||
| P2093 | author name string | Jason K Sicklick | |
| Shumei Kato | |||
| Lyudmila Bazhenova | |||
| Amélie Boichard | |||
| P2860 | cites work | Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 |
| P577 | publication date | 2018-11-15 | |
| P1433 | published in | JCO Precision Oncology | Q89051819 |
| P1476 | title | Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics | |
| P478 | volume | 2018 |
| Q98184336 | Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization |
| Q93016751 | Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma |
| Q91344944 | Development and validation of a targeted gene sequencing panel for application to disparate cancers |
| Q93066081 | Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases |
| Q91981740 | Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours |
| Q91981735 | Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials |
| Q100426629 | From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm |
| Q91199443 | From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer |
| Q90243401 | H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines |
| Q96302702 | Histology-agnostic drug development - considering issues beyond the tissue |
| Q92891966 | Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion |
| Q91737675 | Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer |
| Q91842359 | Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours |
| Q92924197 | NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target |
| Q89543367 | NTRK fusions in osteosarcoma are rare and non-functional events |
| Q91831006 | Optimizing biologic sequencing in metastatic colorectal cancer: first line and beyond |
| Q93139016 | Pancreatic cancer and melanoma related perceptions and behaviors following disclosure of CDKN2A variant status as a research result |
| Q93064832 | Phase I trials as valid therapeutic options for patients with cancer |
| Q100427914 | Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy |
| Q90262410 | Revisiting NTRKs as an emerging oncogene in hematological malignancies |
| Q92633091 | Roles of TrkC Signaling in the Regulation of Tumorigenicity and Metastasis of Cancer |
| Q100526333 | Targetable gene fusions and aberrations in genitourinary oncology |
| Q90943439 | Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays |
| Q90576134 | Towards precision oncology in advanced prostate cancer |
| Q90390840 | Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study |
Search more.